Table 5 Distribution of the studied groups according to treatment
From: Pattern of chronic obstructive pulmonary diseases in Nasser Institute, Egypt
Treatment | Inpatients (n = 90) | Outpatients (n = 110) | ||
|---|---|---|---|---|
No | % | No | % | |
Antibiotic | ||||
No | 1 | 1.1 | 99 | 90 |
Penicillin | 0 | 0.0 | 1 | 0.9 |
Quinolone | 4 | 4.4 | 5 | 4.5 |
Cephalosporin | 83 | 92.2 | 5 | 4.5 |
Cephalosporin and quinolones | 2 | 1.8 | 0 | 0.0 |
B2 agonist | ||||
No | 6 | 5.4 | 13 | 11.8 |
Oral | 4 | 4.4 | 5 | 4.5 |
Inhalers | 0 | 0 | 92 | 83.6 |
Nebuliser | 80 | 88.8 | 0 | 0 |
Xanthines | ||||
No | 0 | 0.0 | 12 | 10.9 |
IV | 0 | 0.0 | 0 | 0.0 |
Oral (SR) | 90 | 100.0 | 98 | 89 |
Steroid | ||||
No | 3 | 3.3 | 15 | 13.6 |
Oral | 27 | 30 | 9 | 8.1 |
Inhaler | 0 | 0 | 82 | 74.5 |
IV | 35 | 38.8 | 4 | 3.6 |
Nebuliser | 25 | 27.7 | 0 | 0 |
Anticholinergic inhaler | ||||
No | 9 | 10 | 108 | 98.1 |
Tiotropium bromide | 0 | 0.0 | 1 | 0.9 |
Ipratropium bromide | 81 | 90 | 1 | 0.9 |
Others | ||||
No | 0 | 0.0 | 7 | 6.3 |
Antitussive | 0 | 0.0 | 1 | 0.9 |
Expectorant | 15 | 16.6 | 43 | 39 |
Mucolytic | 39 | 43.3 | 46 | 41.8 |
Mucolytic and expectorant | 36 | 40 | 13 | 11.8 |